rt-PA静脉溶栓治疗50例急性脑梗死疗效及安全性分析  

The efficacy and safety analysis of 50 cases of acute cerebral infarction by intravenous thrombolysis with recombinant tissue plasminogen activator( rt-PA)

作　　者：欧阳取平[1] 安婷[1] 

机构地区：[1]北京市顺义区医院神经内二科,北京101300

出　　处：《脑与神经疾病杂志》2014年第3期206-209,共4页Journal of Brain and Nervous Diseases

摘　　要：目的探讨重组组织型纤溶酶原激活剂(rt-PA)静脉溶栓治疗急性脑梗死的临床效果及安全性。方法选择发病在4.5h内,平均2.86±0.8h内急性脑梗死患者73例,分为两组,溶栓组50例患者给予rt-PA 0.9mg·kg-1·d-1静脉溶栓,常规治疗组23例患者采用抗血小板聚集药物等治疗,比较溶栓和常规治疗后24h、7d及14d美国国立卫生研究院卒中量表(NIHSS)评分并记录不良反应。结果溶栓组治疗后24h、7d及14d时,NIHSS评分较溶栓前及对照组均明显减少,差异有统计学意义(P<0.05);溶栓后头颅MRI/CT及临床表现提示未出现症状性脑出血。结论 rt-PA静脉溶栓治疗发病4.5h内脑梗死是安全有效的。Objective To explore the clinical efficiency and safety of recombinant tissue plasminogen activator （ rt-PA） intravenous thrombolysis for patients with acute cerebral infarction .Methods Choose within 4.5 h （ average 28.6±0 .8） h of the patients with acute cerebral infarction 73 cases, they were divided into thrombolytic treatment group and routine treatment group , Thrombolysis group was given rt -PA 0.9 · kg-1 · d-1 intravenous thrombolysis , routine treatment group used the conventional treatments such as antiplatelet aggregation .The National Institutes of Health Stroke Scale （NIHSS）score were compared before and after treatment of 24 hours,7 days and 14 days, and record adverse reactions .Results Thrombolysis therapy after 24 h, 7 d and 14 d, NIHSS scores were significantly reduced than before thrombolysis and the control group , there were significant differences （ P〈0.05）;There was not appear symptomatic cerebral hemorrhage by cranial MRI /CT and clinical manifestations of prompt after thrombolysis.Conclusion rt-PA intravenous thrombolysis treatment within 4.5 h of the cerebral infarction is safe and effective.

关 键 词：重组组织型纤溶酶原激活剂 静脉溶栓 脑梗死 

分 类 号：R743.32[医药卫生—神经病学与精神病学]